Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$18.99 USD
-0.52 (-2.67%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $19.03 +0.04 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRBP 18.99 -0.52(-2.67%)
Will CRBP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
Other News for CRBP
Mizuho recommends buying Corbus following its drop post-Novo's obesity data
Corbus Pharma plunges 60% following Novo Nordisk weight loss drug data
Cannabis Stock Movers For September 20, 2024
Corbus sinks 61% to $20 after Novo Nordisk weight loss data
Skye Bioscience, Corbus sink after Novo weight loss data